Investor Presentation Q1 2023

85 Investor presentation First three months of 2023 Novo NordiskⓇ Large patient overlaps between diabetes, obesity, and CVD have guided the focused approach in CVD Population overlap between T2D, obesity and CVD ILLUSTRATIVE Focused approach in CVD Atherosclerosis Heart failure ASCVD + HF ~425m people ASCVD 之仆 CRP IL-6 Type 2 diabetes ~537m people Obesity ~764m people Ziltivekimab Heart failure fraction with preserved ejection amyloid cardiomyopathy Transthyretin (ATTR-CM) (HFPEF) > > > Treatments investigated Semaglutide 2.4 mg Ziltivekimab PRX004 T2D: Type 2 diabetes, CVD: Cardiovascular disease; ASCVD: Atherosclerotic cardiovascular disease; HF: Heart failure; ATTR-CM: Transthyretin Amyloid Cardiomyopathy; LDL-C: Low-density lipoprotein cholesterol; hsCRP: High-sensitivity C-reactive protein Sources: IDF Diabetes Atlas 2021, internal estimate based on European Cardiovascular Disease Statistics, 2017 edition, WHO obesity and overweight fact sheet, 9 June 2021

View entire presentation